Skip to main content

Factors Related to the Assignment of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) versus Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)

    Basic Details
    Date Posted
    Medical Product
    sodium-glucose cotransporter-2 (SGLT-2) inhibitor
    Health Outcome(s)
    factors for treatment assignment

    In this request we examined factors related to the initiation of sodium glucose cotransporter-2 inhibitors (SGLT-2i) versus dipeptidyl peptidase-4 inhibitors (DPP-4i) using varying incidence requirements for the definition of initiation in the Sentinel Distributed Database (SDD). Site, demographic, and clinical factors were examined. We estimated odds ratios for the initiation of SGLT-2i over DPP-4i. We also repeated the analyses to compare use of canagliflozin over dapagliflozin, and of canagliflozin over empagliflozin.

    We distributed this request to eight Sentinel Data Partners on December 3, 2019. The study included data from March 1, 2013 through December 31, 2018.

    The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.

    Additional Details
    FDA Center
    Time Period
    March 1, 2013 - December 31, 2018
    Analysis Type
    Retrospective Inferential
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)